Related Experiment Video

Updated: Nov 8, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.8K

miR-21: A Key Small Molecule with Great Effects in Combination Cancer Therapy

Nahid Arghiani1, Maryam M Matin1,2

  • 1Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.

Nucleic Acid Therapeutics
|April 23, 2021
PubMed

Insights

MicroRNAs (miRNAs) are crucial in cancer. Targeting miR-21, a microRNA elevated in many cancers, shows promise for enhancing chemotherapy efficacy and overcoming drug resistance in cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cancer incidence is rising, necessitating novel diagnostic markers and treatments.
  • MicroRNAs (miRNAs) are small noncoding RNAs with significant potential in cancer diagnostics and therapeutics.
  • miR-21 is frequently overexpressed in various cancers, contributing to proliferation, metastasis, and drug resistance.

Purpose of the Study:

  • To review the role and significance of miR-21 in diverse cancers.
  • To explore miR-21's function in mediating cancer cell drug resistance.
  • To discuss the clinical translation challenges and prospects of anti-miR-21 therapies in combination cancer treatment.

Main Methods:

  • Literature review of studies on miR-21 in cancer.
  • Analysis of miR-21's role in cancer progression and drug resistance.
  • Evaluation of preclinical and clinical data regarding anti-miR-21 strategies.

Main Results:

  • miR-21 overexpression is linked to increased cancer cell proliferation, metastasis, and resistance to chemotherapy.
  • Targeting miR-21, particularly in combination with conventional agents, has demonstrated enhanced therapeutic efficacy in preclinical models.
  • Studies show that inhibiting miR-21 can overcome drug resistance and reduce cancer recurrence.

Conclusions:

  • miR-21 is a critical factor in multiple cancer types and drug resistance.
  • Anti-miR-21 strategies hold promise as a therapeutic approach, especially when combined with existing chemotherapy.
  • Further research and clinical trials are needed to overcome challenges in the translation of anti-miR-21 therapies for effective combination cancer treatment.
Keywords:
cancercombination therapydrug resistancemiR-21

More Related Videos

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method

Published on: October 7, 2025

105
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.2K